Oxford, UK – 5 May 2015: Oxford BioMedica plc (LSE: OXB) (“the Group”), a leading gene and cell therapy group, today announces that Professor Stéphane Palfi MD, PhD has presented a summary of the results from the 12 months and long term (three years) follow up of the 15 patients in the Phase I/II study of ProSavin®, a lentiviral vector based treatment for advanced Parkinson’s disease. Professor Palfi gave an oral presentation of the results at the American Association of Neurological Surgeons (AANS) conference on 4 May 2015 in Washington DC, USA.
The Phase I/II study was designed to evaluate the safety and tolerability of ProSavin® for the treatment of advanced Parkinson’s disease at numerous time points including one, three, six, nine, 12 and 36 months post single injection. ProSavin® was administered to 15 patients by MRI-guided stereotactic injection to the striatum. The study consisted of three dose cohorts.
As previously announced, and as reported in The Lancet in January 2014, ProSavin® met the endpoint of safety and tolerability at all dose levels. A significant improvement in mean unified Parkinson's disease rating scale (UPDRS) part III motor scores in the off medication was observed at six and 12 months compared to baseline in all patients, and this was sustained in the majority of patients for up to three years in the long-term follow up analysis in this progressively degenerative disease. The open-label follow-up study is running to assess long-term (up to 9 years) safety data. The data supports the continued development of an enhanced construct of ProSavin®, OXB-102, as a treatment for advanced Parkinson’s disease.
John Dawson, Chief Executive Officer of Oxford BioMedica, said:
“This summarised data demonstrates that our LentiVector® platform can safely and effectively deliver genes over a long period for the treatment of Parkinson’s disease, resulting in clinical benefit. We are pleased that Professor Palfi presented this Phase I/II study data at 12 months and three years at the prestigious neurosurgical AANS conference.”
Commenting on the three year data, Professor Stéphane Palfi said:
"The continued safety profile of ProSavin® at three years follow-up for all patients and the signs of long-term benefit are still very encouraging in this neurodegenerative disease."
Lancet. 2014 Mar 29;383(9923):1138-46. doi: 10.1016/S0140-6736(13)61939-X. Epub 2014 Jan 10.
Notes to editors
About Oxford BioMedica®
Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy company focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the “Group”) have built a sector leading lentiviral vector delivery platform (LentiVector®) through which the Group develops in vivo and ex-vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Sanofi, GSK, and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 250 people. Further information is available at www.oxfordbiomedica.co.uk.
For further information please contact
Oxford BioMedica plc
John Dawson, Chief Executive Officer
Stuart Paynter, Chief Financial Officer
Tel: +44 (0)1865 783 000
Consilium Strategic Communications – Media Enquiries:
Mary-Jane Elliott/Matthew Neal/Philippa Gardner/Laura Thornton
Tel: +44 (0)20 3709 5700
Peel Hunt (Joint Corporate Brokers):
James Steel/Christopher Golden
Tel: +44 (0)20 7418 8900
WG Partners (Joint Corporate Brokers):
David Wilson/Claes Spang
Tel: +44 (0)20 3705 9321